Part VIII
Prospects
Chapter 22: Molecular Imaging Using Radionanomedicine
Chapter 23: Therapeutic/Theranostic Use of Radionanomedicine
In this part, the eternal goal of radionanomedicine is explained. I, as editor of this
book, coauthored these two chapters. I can assure you that the readers will feel the
direction of radionanomedicine, one is for molecular imaging and the other is for
therapeutic application which should be translated to the clinics for human use to
classify the diseases and to predict the prognosis which are the premises of nuclear
medicine as well as radiology/ diagnostic imaging. The credit of nuclear medicine
goes into its pioneering activities of personalizing the therapeutic options based on
diagnostic or theranostic imaging with personalized dosimetry. Development of
instruments even for the small animals and refinement of tracer kinetic analysis was
the bases of this capability of nuclear medicine and nuclear medicine is now
adopting the outputs of nanotechnology researches and products thereof, as
radionanomedicines, once radiolabeled, the products are going to be the substances
to be able to be used for clinical tomographic quantitative imaging and therapy.
These two chapters were coauthored by my youngest nuclear medicine physician
colleagues and the readers can feel the hue of the future direction of radionanomedicine from the perspectives of the next generation. I am sure that the next
generation nuclear medicine physicians and nanomedicine experts, scientists, and
engineers will bring the field to the clinical ones, eventually.
I wish the direction should be in developing personalized theranostics, which
means that therapeutics are going to be imaged for their in vivo behaviors
elucidating the molecular impact of the radionanomedicine therapeutics.
Radionanomedicines as theranostics and therapeutics are now to be tested for their
Prospects
Chapter 22: Molecular Imaging Using Radionanomedicine
Chapter 23: Therapeutic/Theranostic Use of Radionanomedicine
In this part, the eternal goal of radionanomedicine is explained. I, as editor of this
book, coauthored these two chapters. I can assure you that the readers will feel the
direction of radionanomedicine, one is for molecular imaging and the other is for
therapeutic application which should be translated to the clinics for human use to
classify the diseases and to predict the prognosis which are the premises of nuclear
medicine as well as radiology/ diagnostic imaging. The credit of nuclear medicine
goes into its pioneering activities of personalizing the therapeutic options based on
diagnostic or theranostic imaging with personalized dosimetry. Development of
instruments even for the small animals and refinement of tracer kinetic analysis was
the bases of this capability of nuclear medicine and nuclear medicine is now
adopting the outputs of nanotechnology researches and products thereof, as
radionanomedicines, once radiolabeled, the products are going to be the substances
to be able to be used for clinical tomographic quantitative imaging and therapy.
These two chapters were coauthored by my youngest nuclear medicine physician
colleagues and the readers can feel the hue of the future direction of radionanomedicine from the perspectives of the next generation. I am sure that the next
generation nuclear medicine physicians and nanomedicine experts, scientists, and
engineers will bring the field to the clinical ones, eventually.
I wish the direction should be in developing personalized theranostics, which
means that therapeutics are going to be imaged for their in vivo behaviors
elucidating the molecular impact of the radionanomedicine therapeutics.
Radionanomedicines as theranostics and therapeutics are now to be tested for their